The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key assets underway: olanzapine for treatment of schizophrenia, ...

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Neurocrine Biosciences in ...

Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Subtle signs of neurodegeneration can be detected in blood, CSF, and neuroimaging, up to 20 years before the motor symptoms ...

A little more than a third (36.1%) of patients with Huntington disease (HD) and chorea are taking an anti-chorea medication, a study found.

Those affected appear to have their body parts move as if they are dancing, which has earned it the nickname "chorea." As of 2022, there are only 340 domestic patients with this rare disease.

Mathematician John Napier predicts end of the world in 1688 or 1700. 1728: John Gay’s “The Beggar’s Opera” premieres ...

The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital ...